Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Background Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment. Method Outpatients diagnosed with DSM-IV major depressive disorder (male or female, aged 18 to 81 years) who had completed 8 weeks of randomized double-blind treatment with escitalopram, citalopram, or placebo entered an 8-week flexible-dose, open-label phase in which all patients received escitalopram (10-20 mg/day). This study was initiated November 3, 1999, and completed April 5, 2001. Patients who met responder criteria (score of or = 22 or discontinuation due to an insufficient therapeutic response) from the start of the double-blind treatment phase. Results A total of 502 patients received open-label escitalopram treatment and had at least 1 MADRS assessment. A total of 274 evaluable subjects entered the double-blind treatment phase; 93 received placebo and 181 received escitalopram. Time to depression relapse was significantly longer (p =.013) and the cumulative rate of relapse was significantly lower in patients who received escitalopram (26% escitalopram vs. 40% placebo; hazard ratio = 0.56; p =.01). Escitalopram-treated subjects had significantly lower depression ratings than those of placebo-treated patients. Escitalopram continuation treatment was safe and well tolerated. Discontinuation rates due to adverse events we…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The original DBRPCTs reported that although vilazodone did not differ from placebo in terms of relapse rate at the study-endpoint [23], escitalopram and bupropion were superior to placebo [43, 55].”
From Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis (2023) · cites this paper as [43]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
(1996) · Cited by 6,884
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
Burke, W. J., Gergel, I., & Bose, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0410 · Cited by 350
Self-citationContinuation drug therapy for major depressive episodes: how long should it be maintained?
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.1.18 · Cited by 295
Keller, M. B., & Boland, R. J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00110-3 · Cited by 281
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Cited by
Items 101–121 of 121
Bauer, K. H. (2010) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-827 · Cited by 4
Pan, Z., Zhang, H., Li, B., Huang, Z., Hu, Y., Chen, J., Lam, R. W. M., & Fang, Y. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119460 · Cited by 3
Schmitt, L., Arbus, C., & Tonnoir, B. (2006) · L Encéphale · doi:10.1016/s0013-7006(06)76154-1 · Cited by 2
Mishra, S., Mudgal, V., Bagul, K. R., Jain, P., & Pal, V. (2025) · Cureus · doi:10.7759/cureus.79365 · Cited by 1
Therapy of cardioneurosis with modern antidepressants in general medical care network
Medvedev, V. E., Фролова, В. И., & Котова, О. В. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-25-26-32 · Cited by 1
Chapter 14. Citalopram and Escitalopram
Shelton, R. C. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as14 · Cited by 1
Current treatment options: relief of symptoms and ultimate recovery
Kennedy, S. H. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600552503 · Cited by 1
Psychopharmakotherapie — Klinisch-empirische Grundlagen
Kasper, S., & Möller, H. ‐. (2007) · Springer eBooks · doi:10.1007/978-3-540-33129-2_27 · Cited by 1
Depression : can we predict who will relapse?
Buckman, J. E. J. (2014) · UCL Discovery (University College London) · Cited by 2
Jin, Y. (2010) · D-Scholarship@Pitt (University of Pittsburgh)
Escitalopram, un développement clinique complet
Dijck, P. V. (2007) · L Encéphale · doi:10.1016/s0013-7006(07)78687-6
McIntyre, R. S., Fayyad, R. S., Guico‐Pabia, C. J., & Boucher, M. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01681
Velasco, M., Salvador, L., Juárez-Castelló, C. A., & Antoñanzas, F. (2006) · PharmacoEconomics Spanish Research Articles · doi:10.1007/bf03320911
Andersen, H. F., Lam, R. W. M., & Kennedy, S. H. (2006) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.9938
Shinde, M. (2018) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v6i3.219
Khaustova, O. O. (2018) · Medicine of Ukraine · doi:10.37987/1997-9894.2018.3(219).198452 · Cited by 1
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. ‐. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_31-1
Current awareness in human psychopharmacology
(2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.632
Дифференцированная психофармакотерапия рекуррентного депрессивного расстройства на этапе ремиссии
Zakharova, N. V. (2015) · Psikhiatriya · doi:10.30629/2618-6667-2015-67-32-41 · Cited by 1
Sibut, R., & Lachal, J. (2026) · Adolescent Psychiatry · doi:10.2174/0122106766389831251028050556
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.028
Metadata
- Authors
- Rapaport, M. H., Bose, A., & Zheng, H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-01-15
- Volume
- 65
- Issue
- 1
- Pages
- 44-49
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2077027462
- Cited by
- 121
- References
- 24
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 6 · 2014: 5 · 2013: 1 · 2012: 3
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- escitalopram, continuation treatment, relapse prevention, major depressive disorder, antidepressant efficacy, citalopram, open-label extension, adverse events, treatment safety
- MeSH terms
- Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Placebos, Prognosis, Psychiatric Status Rating Scales, Recurrence, Citalopram, Treatment Outcome, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.